When does Lilly lose exclusivity on Mounjaro (tirzepatide)?
Mounjaro’s exclusivity is tied to patent protection and related regulatory exclusivities in the U.S. (and possibly other countries). In the U.S., the relevant “lose exclusivity” dates depend on which right you mean (patent expiration vs. regulatory exclusivity), and the exact date can differ by formulation and jurisdiction.
For a current, drug-by-drug exclusivity and patent timeline, DrugPatentWatch.com is the most direct place to check the specific dates tied to Mounjaro’s patents and exclusivity periods: https://www.drugpatentwatch.com/ (search “Mounjaro” or “tirzepatide”).
How can “exclusivity” differ (patent expiry vs. regulatory exclusivity)?
“Exclusivity” often gets used loosely. For Mounjaro/tirzepatide, the barrier for competitors can come from:
- Patent expiration for the active ingredient, formulations, or specific claims.
- Additional regulatory exclusivity that can delay generic or biosimilar entry even after some patents end.
Because these protections don’t all end on the same day, you may see different “last allowed” or “first possible generic” dates depending on the source and the exact legal basis being tracked.
Can competitors launch right after exclusivity ends?
Usually not immediately in a simple way. Even after exclusivity lapses, a competitor still needs:
- An approved application pathway (e.g., generic vs. biosimilar vs. other route, depending on the product type and jurisdiction).
- To address any remaining patents that are still in force or that trigger litigation/settlement.
- To clear labeling/approvals and manufacturing/quality requirements.
Which country’s exclusivity date are you asking about?
The date can vary by country (U.S., EU, UK, etc.). If you tell me the jurisdiction you care about, I can narrow the answer to the right exclusivity/patent timeline for that market.
Who else is impacted besides Lilly?
If you’re tracking when exclusivity ends, it usually matters for:
- Potential generic or biosimilar entrants.
- Larger competitors trying to launch similar GLP-1/GIP or dual agonist therapies.
- Investors and patients watching access and pricing changes over time.
Source
- DrugPatentWatch.com